Keep pulling the thread on Josh Fink.
Character Biosciences has developed a therapy that is a potential cure for both dry and wet macular degeneration.
The rapid advancement of China's biotech industry is considered a national security issue for the United States.
Luma Group has developed a proprietary tool named Labby, which is designed to parse both preclinical and clinical data.
Luma Group's investment strategy focuses on companies that have already generated significant amounts of preclinical data, rather than investing in raw science.
Luma Group's investment model involves leading funding rounds, becoming a top investor, syndicating the round, and bringing in large pharmaceutical companies as partners.
Luma Group led the Series B funding round for Character Biosciences in 2025.
Character Biosciences's therapy for macular degeneration was developed using AI to analyze large quantities of longitudinal eye data, a feat that would not have otherwise been possible.
The therapy for macular degeneration developed by Character Biosciences is currently being dosed in humans in Phase 1 clinical trials.
Eli Lilly has successfully caught up to Novo Nordisk in the competitive GLP-1 drug market.
The United States risks losing its leadership position in biotechnology if it fails to enshrine intellectual property rights for new drugs discovered using AI.
China's biotech industry has evolved from copying existing drugs to producing genuine de novo innovation.
The United States is currently the undisputed global leader in biotechnology development.